Vanderbilt University School of Medicine

Roden, Dan M. , M.D.
Assistant Vice Chancellor for Personalized Medicine
Professor of Medicine
William Stokes Chair in Experimental Therapeutics
Professor of Pharmacology

Lab Url: http://oates.mc.vanderbilt.edu/rodenlab/index.php

Phone Number: 615-322-0067

Email Address:dan.roden@vanderbilt.edu

Roden, Dan's picture

Office Address   Mailing Address

1285 Medical Research Building IV

1285-B MRB4 37232-0575


Research Keywords
Drug metabolism, Genetics, Heart, Ion transport, Knockout, Mouse, Pharmacokinetics, Pharmacology, Polymorphism

Research Specialty
Mechanisms and treatment of cardiac arrhythmias

Research Description
Abnormalities of cardiac rhythm are a common and serious public health problem. However, the therapies used to treat arrhythmias are often ineffective, and can sometimes even exacerbate arrhythmias. Research in this laboratory is directed at elucidating mechanisms underlying abnormalities of cardiac rhythm and mechanisms underlying variable responses to antiarrhythmic drug treatments. Since antiarrhythmic drugs affect the function of cardiac ion channels, it is one working hypothesis in the laboratory that variable responses to drug therapy may reflect variable function or expression of genes encoding ion channels or proteins involved in drug disposition. Thus, a major focus of work in the laboratory is elucidation of factor(s) that determine ion channel gene expression in cardiac tissue. Approaches include identification of new genes, identification of DNA polymorphisms and characterization of their functional effects on disease and drug responses, and modulation of expression in cultured heart cells (e.g. by antisense) and gene knockout in mice.

Clinical Interests
We are interested in variability in arrhythmia presentations and their response to therapies, particularly as a function of genetic background.

Publications
Delaney, JT, Jeff, JM, Brown, NJ, Pretorius, M, Okafor, HE, Darbar, D, Roden, DM, Crawford, DC. Characterization of genome-wide association-identified variants for atrial fibrillation in African Americans. PLoS One, 7(2), e32338, 2012. PMCID:3285683

Delaney, JT, Muhammad, R, Blair, MA, Kor, K, Fish, FA, Roden, DM, Darbar, D. A KCNJ8 mutation associated with early repolarization and atrial fibrillation. Europace, , , 2012.

Delaney, JT, Ramirez, AH, Bowton, E, Pulley, JM, Basford, MA, Schildcrout, JS, Shi, Y, Zink, R, Oetjens, M, Xu, H, Cleator, JH, Jahangir, E, Ritchie, MD, Masys, DR, Roden, DM, Crawford, DC, Denny, JC. Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther, 91(2), 257-63, 2012. PMCID:3243123

Lowe, JS, Stroud, DM, Yang, T, Hall, L, Atack, TC, Roden, DM. Increased late sodium current contributes to long QT-related arrhythmia susceptibility in female mice. Cardiovasc Res, , , 2012.

Monahan, K, Brewster, J, Wang, L, Parvez, B, Goyal, S, Roden, DM, Darbar, D. Relation of the Severity of Obstructive Sleep Apnea in Response to Anti-Arrhythmic Drugs in Patients With Atrial Fibrillation or Atrial Flutter. Am J Cardiol, , , 2012.

Parvez, B, Chopra, N, Rowan, S, Vaglio, JC, Muhammad, R, Roden, DM, Darbar, D. A common I?1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol, 59(1), 49-56, 2012. PMCID:3243123

Pulley, JM, Denny, JC, Peterson, JF, Bernard, GR, Vnencak-Jones, CL, Ramirez, AH, Delaney, JT, Bowton, E, Brothers, K, Johnson, K, Crawford, DC, Schildcrout, J, Masys, DR, Dilks, HH, Wilke, RA, Clayton, EW, Shultz, E, Laposata, M, McPherson, J, Jirjis, JN, Roden, DM. Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project. Clin Pharmacol Ther, 92(1), 87-95, 2012. PMCID:3384438

Ramirez, AH, Shaffer, CM, Delaney, JT, Sexton, DP, Levy, SE, Rieder, MJ, Nickerson, DA, George, AL, Roden, DM. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J, , , 2012. PMCID:3384438

Ramirez, AH, Shi, Y, Schildcrout, JS, Delaney, JT, Xu, H, Oetjens, MT, Zuvich, RL, Basford, MA, Bowton, E, Jiang, M, Speltz, P, Zink, R, Cowan, J, Pulley, JM, Ritchie, MD, Masys, DR, Roden, DM, Crawford, DC, Denny, JC. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics, 13(4), 407-18, 2012. PMCID:3285683

Ritchie, MD, Rowan, S, Kucera, G, Stubblefield, T, Blair, M, Carter, S, Roden, DM, Darbar, D. Chromosome 4q25 Variants Are Genetic Modifiers of Rare Ion Channel Mutations Associated With Familial Atrial Fibrillation. J Am Coll Cardiol, , , 2012.

Roden, DM, Xu, H, Denny, JC, Wilke, RA. Electronic Medical Records as a Tool in Clinical Pharmacology: Opportunities and Challenges. Clin Pharmacol Ther, , , 2012.

Schildcrout, JS, Denny, JC, Bowton, E, Gregg, W, Pulley, JM, Basford, MA, Cowan, JD, Xu, H, Ramirez, AH, Crawford, DC, Ritchie, MD, Peterson, JF, Masys, DR, Wilke, RA, Roden, DM. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther, 92(2), 235-42, 2012.

Wells, QS, Delaney, JT, Roden, DM. Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol, 27(3), 253-61, 2012. PMCID:3285683

Wilke, RA, Ramsey, LB, Johnson, SG, Maxwell, WD, McLeod, HL, Voora, D, Krauss, RM, Roden, DM, Feng, Q, Cooper-Dehoff, RM, Gong, L, Klein, TE, Wadelius, M, Niemi, M. The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy. Clin Pharmacol Ther, 92(1), 112-7, 2012. PMCID:3384438

Yang, T, Atack, TC, Stroud, DM, Zhang, W, Hall, L, Roden, DM. Blocking scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res, 111(3), 322-32, 2012.

Atack, TC, Stroud, DM, Watanabe, H, Yang, T, Hall, L, Hipkens, SB, Lowe, JS, Leake, B, Magnuson, MA, Yang, P, Roden, DM. Informatic and functional approaches to identifying a regulatory region for the cardiac sodium channel. Circ Res, 109(1), 38-46, 2011. PMCID:3092760

Barrett, TW, Storrow, AB, Jenkins, CA, Harrell, FE, Miller, KF, Moser, KM, Russ, S, Roden, DM, Darbar, D. Atrial fibrillation and flutter outcomes and risk determination (AFFORD): design and rationale. J Cardiol, 58(2), 124-30, 2011. PMCID:3188836

Denny, JC, Crawford, DC, Ritchie, MD, Bielinski, SJ, Basford, MA, Bradford, Y, Chai, HS, Bastarache, L, Zuvich, R, Peissig, P, Carrell, D, Ramirez, AH, Pathak, J, Wilke, RA, Rasmussen, L, Wang, X, Pacheco, JA, Kho, AN, Hayes, MG, Weston, N, Matsumoto, M, Kopp, PA, Newton, KM, Jarvik, GP, Li, R, Manolio, TA, Kullo, IJ, Chute, CG, Chisholm, RL, Larson, EB, McCarty, CA, Masys, DR, Roden, DM, de Andrade, M. Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet, 89(4), 529-42, 2011. PMCID:3188836

Kannankeril, PJ, Norris, KJ, Carter, S, Roden, DM. Factors affecting the degree of QT prolongation with drug challenge in a large cohort of normal volunteers. Heart Rhythm, 8(10), 1530-4, 2011. PMCID:3093198

Liu, M, Jiang, M, Kawai, VK, Stein, CM, Roden, DM, Denny, JC, Xu, H. Modeling drug exposure data in electronic medical records: an application to warfarin. AMIA Annu Symp Proc, 2011, 815-23, 2011. PMCID:3243123

Roden, DM. Personalized medicine and the genotype-phenotype dilemma. J Interv Card Electrophysiol, 31(1), 17-23, 2011. PMCID:3093198

Roden, DM, Johnson, JA, Kimmel, SE, Krauss, RM, Medina, MW, Shuldiner, A, Wilke, RA. Cardiovascular pharmacogenomics. Circ Res, 109(7), 807-20, 2011. PMCID:3188836

Roden, DM, Wilke, RA, Kroemer, HK, Stein, CM. Pharmacogenomics: the genetics of variable drug responses. Circulation, 123(15), 1661-70, 2011. PMCID:3093198

Turner, SD, Berg, RL, Linneman, JG, Peissig, PL, Crawford, DC, Denny, JC, Roden, DM, McCarty, CA, Ritchie, MD, Wilke, RA. Knowledge-driven multi-locus analysis reveals gene-gene interactions influencing HDL cholesterol level in two independent EMR-linked biobanks. PLoS One, 6(5), e19586, 2011. PMCID:3092760

Watanabe, H, Yang, T, Stroud, DM, Lowe, JS, Harris, L, Atack, TC, Wang, DW, Hipkens, SB, Leake, B, Hall, L, Kupershmidt, S, Chopra, N, Magnuson, MA, Tanabe, N, Knollmann, BC, George, AL, Roden, DM. Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro. Circulation, 124(9), 1001-11, 2011. PMCID:3188836

Xu, H, Jiang, M, Oetjens, M, Bowton, EA, Ramirez, AH, Jeff, JM, Basford, MA, Pulley, JM, Cowan, JD, Wang, X, Ritchie, MD, Masys, DR, Roden, DM, Crawford, DC, Denny, JC. Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. J Am Med Inform Assoc, 18(4), 387-91, 2011. PMCID:3188836

Abraham, RL, Yang, T, Blair, M, Roden, DM, Darbar, D. Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. J Mol Cell Cardiol, 48(1), 181-90, 2010. PMCID:2740737

Chopra, SS, Stroud, DM, Watanabe, H, Bennett, JS, Burns, CG, Wells, KS, Yang, T, Zhong, TP, Roden, DM. Voltage-gated sodium channels are required for heart development in zebrafish. Circ Res, 106(8), 1342-50, 2010.

Denny, JC, Ritchie, MD, Basford, MA, Pulley, JM, Bastarache, L, Brown-Gentry, K, Wang, D, Masys, DR, Roden, DM, Crawford, DC. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics, 26(9), 1205-10, 2010. PMCID:2859132

Drew, BJ, Ackerman, MJ, Funk, M, Gibler, WB, Kligfield, P, Menon, V, Philippides, GJ, Roden, DM, Zareba, W, , . Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation, 121(8), 1047-60, 2010. PMCID:2859132

Drew, BJ, Ackerman, MJ, Funk, M, Gibler, WB, Kligfield, P, Menon, V, Philippides, GJ, Roden, DM, Zareba, W, , , , , , . Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol, 55(9), 934-47, 2010. PMCID:2859132

Ellinor, PT, Lunetta, KL, Glazer, NL, Pfeufer, A, Alonso, A, Chung, MK, Sinner, MF, de Bakker, PI, Mueller, M, Lubitz, SA, Fox, E, Darbar, D, Smith, NL, Smith, JD, Schnabel, RB, Soliman, EZ, Rice, KM, Van Wagoner, DR, Beckmann, BM, van Noord, C, Wang, K, Ehret, GB, Rotter, JI, Hazen, SL, Steinbeck, G, Smith, AV, Launer, LJ, Harris, TB, Makino, S, Nelis, M, Milan, DJ, Perz, S, Esko, T, K??ttgen, A, Moebus, S, Newton-Cheh, C, Li, M, M??hlenkamp, S, Wang, TJ, Kao, WH, Vasan, RS, N??then, MM, MacRae, CA, Stricker, BH, Hofman, A, Uitterlinden, AG, Levy, D, Boerwinkle, E, Metspalu, A, Topol, EJ, Chakravarti, A, Gudnason, V, Psaty, BM, Roden, DM, Meitinger, T, Wichmann, HE, Witteman, JC, Barnard, J, Arking, DE, Benjamin, EJ, Heckbert, SR, K????b, S. Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet, 42(3), 240-4, 2010. PMCID:2859132

Limdi, NA, Wadelius, M, Cavallari, L, Eriksson, N, Crawford, DC, Lee, MT, Chen, CH, Motsinger-Reif, A, Sagreiya, H, Liu, N, Wu, AH, Gage, BF, Jorgensen, A, Pirmohamed, M, Shin, JG, Suarez-Kurtz, G, Kimmel, SE, Johnson, JA, Klein, TE, Wagner, MJ, , . Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood, 115(18), 3827-34, 2010. PMCID:2859132

Oshiro, C, Thorn, CF, Roden, DM, Klein, TE, Altman, RB. KCNH2 pharmacogenomics summary. Pharmacogenet Genomics, , , 2010. PMCID:2859132

Pulley, J, Clayton, E, Bernard, GR, Roden, DM, Masys, DR. Principles of human subjects protections applied in an opt-out, de-identified biobank. Clin Transl Sci, 3(1), 42-8, 2010.

Ritchie, MD, Denny, JC, Crawford, DC, Ramirez, AH, Weiner, JB, Pulley, JM, Basford, MA, Brown-Gentry, K, Balser, JR, Masys, DR, Haines, JL, Roden, DM. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am J Hum Genet, 86(4), 560-72, 2010.

Roden, DM. Brugada syndrome: lots of questions, some answers. Heart Rhythm, 7(1), 47-9, 2010. PMCID:2859132

Body, SC, Collard, CD, Shernan, SK, Fox, AA, Liu, KY, Ritchie, MD, Perry, TE, Muehlschlegel, JD, Aranki, S, Donahue, BS, Pretorius, M, Estrada, JC, Ellinor, PT, Newton-Cheh, C, Seidman, CE, Seidman, JG, Herman, DS, Lichtner, P, Meitinger, T, Pfeufer, A, K????b, S, Brown, NJ, Roden, DM, Darbar, D. Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery. Circ Cardiovasc Genet, 2(5), 499-506, 2009. PMCID:2801871

Bush, WS, Crawford, DC, Alexander, C, George, AL, Roden, DM, Ritchie, MD. Genetic variation in the rhythmonome: ethnic variation and haplotype structure in candidate genes for arrhythmias. Pharmacogenomics, 10(6), 1043-53, 2009. PMCID:2746955

K????b, S, Darbar, D, van Noord, C, Dupuis, J, Pfeufer, A, Newton-Cheh, C, Schnabel, R, Makino, S, Sinner, MF, Kannankeril, PJ, Beckmann, BM, Choudry, S, Donahue, BS, Heeringa, J, Perz, S, Lunetta, KL, Larson, MG, Levy, D, MacRae, CA, Ruskin, JN, Wacker, A, Sch??mig, A, Wichmann, HE, Steinbeck, G, Meitinger, T, Uitterlinden, AG, Witteman, JC, Roden, DM, Benjamin, EJ, Ellinor, PT. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J, 30(7), 813-9, 2009. PMCID:2663727

Li, C, Schwarz, UI, Ritchie, MD, Roden, DM, Stein, CM, Kurnik, D. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood, 113(17), 3925-30, 2009. PMCID:2673121

McBride, BF, Yang, T, Roden, DM. Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. Pharmacogenomics J, 9(3), 194-201, 2009. PMCID:2746955

Milan, DJ, Kim, AM, Winterfield, JR, Jones, IL, Pfeufer, A, Sanna, S, Arking, DE, Amsterdam, AH, Sabeh, KM, Mably, JD, Rosenbaum, DS, Peterson, RT, Chakravarti, A, K????b, S, Roden, DM, MacRae, CA. Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation, 120(7), 553-9, 2009. PMCID:2727725

Postema, PG, Wolpert, C, Amin, AS, Probst, V, Borggrefe, M, Roden, DM, Priori, SG, Tan, HL, Hiraoka, M, Brugada, J, Wilde, AA. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm, 6(9), 1335-41, 2009. PMCID:2727725

Raj, SR, Stein, CM, Saavedra, PJ, Roden, DM. Cardiovascular effects of noncardiovascular drugs. Circulation, 120(12), 1123-32, 2009. PMCID:2727725

Roden, DM, Kannankeri, PJ, Darbar, D. Arrhythmia pharmacogenomics: methodological considerations. Curr Pharm Des, 15(32), 3734-41, 2009. PMCID:2788624

Watanabe, H, Chopra, N, Laver, D, Hwang, HS, Davies, SS, Roach, DE, Duff, HJ, Roden, DM, Wilde, AA, Knollmann, BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med, 15(4), 380-3, 2009. PMCID:2746955

Watanabe, H, Darbar, D, Kaiser, DW, Jiramongkolchai, K, Chopra, S, Donahue, BS, Kannankeril, PJ, Roden, DM. Mutations in sodium channel beta1- and beta2-subunits associated with atrial fibrillation. Circ Arrhythm Electrophysiol, 2(3), 268-75, 2009. PMCID:2727725

Watanabe, H, Kaiser, DW, Makino, S, MacRae, CA, Ellinor, PT, Wasserman, BS, Kannankeril, PJ, Donahue, BS, Roden, DM, Darbar, D. ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling. Heart Rhythm, 6(9), 1327-32, 2009. PMCID:2740737

Watanabe, H, Watanabe, T, Sasaki, S, Nagai, K, Roden, DM, Aizawa, Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J, 158(4), 629-36, 2009. PMCID:2727725

Yang, T, Chung, SK, Zhang, W, Mullins, JG, McCulley, CH, Crawford, J, MacCormick, J, Eddy, CA, Shelling, AN, French, JK, Yang, P, Skinner, JR, Roden, DM, Rees, MI. Biophysical properties of 9 KCNQ1 mutations associated with long-QT syndrome. Circ Arrhythm Electrophysiol, 2(4), 417-26, 2009. PMCID:2788624

Yang, T, Kanki, H, Zhang, W, Roden, DM. Probing the mechanisms underlying modulation of quinidine sensitivity to cardiac I(Ks) block by protein kinase A-mediated I(Ks) phosphorylation. Br J Pharmacol, 157(6), 952-61, 2009. PMCID:2746955

Darbar, D, Hardy, A, Haines, JL, Roden, DM. Prolonged signal-averaged P-wave duration as an intermediate phenotype for familial atrial fibrillation. J Am Coll Cardiol, 51(11), 1083-9, 2008. PMCID:2279191

Darbar, D, Kannankeril, PJ, Donahue, BS, Kucera, G, Stubblefield, T, Haines, JL, George, AL, Roden, DM. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation, 117(15), 1927-35, 2008. PMCID:2365761

Darbar, D, Kimbrough, J, Jawaid, A, McCray, R, Ritchie, MD, Roden, DM. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. J Am Coll Cardiol, 51(8), 836-42, 2008. PMCID:2271078

Kannankeril, PJ, Harris, PA, Norris, KJ, Warsy, I, Smith, PD, Roden, DM. Rate-Independent QT Shortening During Exercise in Healthy Subjects: Terminal Repolarization Does Not Shorten with Exercise. J Cardiovasc Electrophysiol, , , 2008.

Knollmann, BC, Roden, DM. A genetic framework for improving arrhythmia therapy. Nature, 451(7181), 929-36, 2008.

Rhodes, TE, Abraham, RL, Welch, RC, Vanoye, CG, Crotti, L, Arnestad, M, Insolia, R, Pedrazzini, M, Ferrandi, C, Vege, A, Rognum, T, Roden, DM, Schwartz, PJ, George, AL. Cardiac potassium channel dysfunction in sudden infant death syndrome. J Mol Cell Cardiol, 44(3), 571-81, 2008. PMCID:2386856

Roden, D, Pulley, J, Basford, M, Bernard, G, Clayton, E, Balser, J, Masys, D. Development of a Large-Scale De-Identified DNA Biobank to Enable Personalized Medicine. Clin Pharmacol Ther, , , 2008.

Roden, DM. Keep the QT interval: it is a reliable predictor of ventricular arrhythmias. Heart Rhythm, 5(8), 1213-5, 2008.

Roden, DM. Cellular basis of drug-induced torsades de pointes. Br J Pharmacol, 154(7), 1502-7, 2008. PMCID:2492095

Roden, DM. Clinical practice. Long-QT syndrome. N Engl J Med, 358(2), 169-76, 2008.

Schwarz, UI, Ritchie, MD, Bradford, Y, Li, C, Dudek, SM, Frye-Anderson, A, Kim, RB, Roden, DM, Stein, CM. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med, 358(10), 999-1008, 2008.

Watanabe, H, Koopmann, TT, Le Scouarnec, S, Yang, T, Ingram, CR, Schott, JJ, Demolombe, S, Probst, V, Anselme, F, Escande, D, Wiesfeld, AC, Pfeufer, A, K????b, S, Wichmann, HE, Hasdemir, C, Aizawa, Y, Wilde, AA, Roden, DM, Bezzina, CR. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest, 118(6), 2260-8, 2008. PMCID:2373423

Yang, P, Koopmann, TT, Pfeufer, A, Jalilzadeh, S, Schulze-Bahr, E, K????b, S, Wilde, AA, Roden, DM, Bezzina, CR. Polymorphisms in the cardiac sodium channel promoter displaying variant in vitro expression activity. Eur J Hum Genet, 16(3), 350-7, 2008.

Chopra, SS, Watanabe, H, Zhong, TP, Roden, DM. Molecular cloning and analysis of zebrafish voltage-gated sodium channel beta subunit genes: implications for the evolution of electrical signaling in vertebrates. BMC Evol Biol, 7, 113, 2007. PMCID:1971062

Darbar, D, Hardin, B, Harris, P, Roden, DM. A rate-independent method of assessing QT-RR slope following conversion of atrial fibrillation. J Cardiovasc Electrophysiol, 18(6), 636-41, 2007.

Darbar, D, Motsinger, AA, Ritchie, MD, Gainer, JV, Roden, DM. Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm, 4(6), 743-9, 2007. PMCID:1948880

Fitch, RW, Gregory, A, Darbar, D, Roden, DM. A shock in time. Clin J Sport Med, 17(6), 497-9, 2007.

Kannankeril, PJ, Roden, DM. When should QT be measured? Summer solstice or Christmas Eve. Heart Rhythm, 4(3), 282-3, 2007.

Kannankeril, PJ, Roden, DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol, 22(1), 39-43, 2007.

Mohler PJ, Le Scouarnec S, Denjoy I, Lowe JS, Guicheney P, Caron L, Schott J-J, Norris K, Kim RB, Escande D, Roden DM:. Dysfunctional ankyrin-B variants with a spectrum of altered function are present in diverse human populations. . Circulation , 115, 432-441, 2007.

Monahan, K, Clair, W, Roden, DM. A memorable experience. Europace, , , 2007.

Pretorius, M, Donahue, BS, Yu, C, Greelish, JP, Roden, DM, Brown, NJ. Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation, 116(11 Suppl), I1-7, 2007.

Roden, DM, Kannankeril, P, Darbar, D. On the relationship among QT interval, atrial fibrillation, and torsade de pointes. Europace, 9 Suppl 4, iv1-3, 2007. PMCID:2599908

Smith, AH, Norris, KJ, Roden, DM, Kannankeril, PJ. Autonomic tone attenuates drug-induced QT prolongation. J Cardiovasc Electrophysiol, 18(9), 960-4, 2007.

Bezzina CR, Shimizu W, Yang P, Koopmann T, Tanck MWT, Miyamoto Y, Kamakura S, Roden DM, Wilde AAM. Common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction. . Circulation , 113, 338-344, 2006.

Darbar, D, Roden, DM. Future of antiarrhythmic drugs. Curr Opin Cardiol, 21(4), 361-7, 2006.

Darbar, D, Roden, DM. Pharmacogenetics of antiarrhythmic therapy. Expert Opin Pharmacother, 7(12), 1583-90, 2006.

Kannankeril, PJ, Bhuiyan, ZA, Darbar, D, Mannens, MM, Wilde, AA, Roden, DM. Arrhythmogenic right ventricular cardiomyopathy due to a novel plakophilin 2 mutation: wide spectrum of disease in mutation carriers within a family. Heart Rhythm, 3(8), 939-44, 2006.

Kannankeril, PJ, Mitchell, BM, Goonasekera, SA, Chelu, MG, Zhang, W, Sood, S, Kearney, DL, Danila, CI, De Biasi, M, Wehrens, XH, Pautler, RG, Roden, DM, Taffet, GE, Dirksen, RT, Anderson, ME, Hamilton, SL. Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc Natl Acad Sci U S A, 103(32), 12179-84, 2006. PMCID:1567715

Knollmann, BC, Chopra, N, Hlaing, T, Akin, B, Yang, T, Ettensohn, K, Knollmann, BE, Horton, KD, Weissman, NJ, Holinstat, I, Zhang, W, Roden, DM, Jones, LR, Franzini-Armstrong, C, Pfeifer, K. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest, 116(9), 2510-20, 2006. PMCID:1551934

Liu, K, Hipkens, S, Yang, T, Abraham, R, Zhang, W, Chopra, N, Knollmann, B, Magnuson, MA, Roden, DM. Recombinase-mediated cassette exchange to rapidly and efficiently generate mice with human cardiac sodium channels. Genesis, 44(11), 556-64, 2006.

Motsinger, AA, Donahue, BS, Brown, NJ, Roden, DM, Ritchie, MD. Risk factor interactions and genetic effects associated with post-operative atrial fibrillation. Pac Symp Biocomput, , 584-95, 2006.

Roden, DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med, 259(1), 59-69, 2006.

Roden, DM, Altman, RB, Benowitz, NL, Flockhart, DA, Giacomini, KM, Johnson, JA, Krauss, RM, McLeod, HL, Ratain, MJ, Relling, MV, Ring, HZ, Shuldiner, AR, Weinshilboum, RM, Weiss, ST, , . Pharmacogenomics: challenges and opportunities. Ann Intern Med, 145(10), 749-57, 2006.

Roden, DM, Anderson, ME. Proarrhythmia. Handb Exp Pharmacol, (171), 73-97, 2006.

Bezzina, CR, Wilde, AA, Roden, DM. The molecular genetics of arrhythmias. Cardiovasc Res, 67(3), 343-6, 2005.

Crotti, L, Lundquist, AL, Insolia, R, Pedrazzini, M, Ferrandi, C, De Ferrari, GM, Vicentini, A, Yang, P, Roden, DM, George, AL, Schwartz, PJ. KCNH2-K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome. Circulation, , , 2005.

Darbar, D, Roden, DM. Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillation. Heart Rhythm, 2(5), 544-9, 2005.

Darbar, D, Roden, DM, Ali, MF, Yang, T, Wathen, MS. Images in cardiovascular medicine. Himalayan T waves in the congenital long-QT syndrome. Circulation, 111(11), e161, 2005.

Darbar, D, Yang, T, Churchwell, K, Wilde, AA, Roden, DM. Unmasking of brugada syndrome by lithium. Circulation, 112(11), 1527-31, 2005. PMCID:1350464

Drolet, B, Simard, C, Mizoue, L, Roden, DM. Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. J Clin Invest, 115(8), 2209-13, 2005. PMCID:1174915

Kannankeril, PJ, Roden, DM, Norris, KJ, Whalen, SP, George, AL, Murray, KT. Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm, 2(2), 134-40, 2005.

Khoo, MS, Kannankeril, PJ, Li, J, Zhang, R, Kupershmidt, S, Zhang, W, Atkinson, JB, Colbran, RJ, Roden, DM, Anderson, ME. Calmodulin kinase II activity is required for normal atrioventricular nodal conduction. Heart Rhythm, 2(6), 634-40, 2005.

Liu, K, Yang, T, Viswanathan, PC, Roden, DM. New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant. Circulation, 112(21), 3239-46, 2005.

Page RL, Roden DM. Drug therapy for atrial fibrillation. . Nature Drug Discovery, 4, 899-910, 2005.

Roden DM. Principles of Clinical Pharmacology. . In Sixteenth Edition of Harrison?s Principles of Internal Medicine, , 13-25, 2005.

Roden DM and Temple R. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process. . Circulation , 111, 1697-1702, 2005.

Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. . J Clin Invest , 115, 2025-2032, 2005.

Roden DM, Yang T. Editorial - Protecting the heart against arrhythmias: potassium current physiology and repolarization reserve. . Circulation , 112, 1376-1378, 2005.

Roden DM:. An under-recognized challenge in evaluating post-marketing drug safety.. Circulation, 111, 246-8, 2005.

Roden, DM. Proarrhythmia as a pharmacogenomic entity: a critical review and formulation of a unifying hypothesis. Cardiovasc Res, 67(3), 419-25, 2005.

Roden, DM. An underrecognized challenge in evaluating postmarketing drug safety. Circulation, 111(3), 246-8, 2005.

Roden, DM, Temple, R. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process. Circulation, 111(13), 1697-702, 2005.

Roden, DM, Viswanathan, PC. Genetics of acquired long QT syndrome. J Clin Invest, 115(8), 2025-32, 2005. PMCID:1180553

Simard, C, Drolet, B, Yang, P, Kim, RB, Roden, DM. Polymorphism screening in the cardiac K+ channel gene KCNA5. Clin Pharmacol Ther, 77(3), 138-44, 2005.

Temple, J, Frias, P, Rottman, J, Yang, T, Wu, Y, Verheijck, EE, Zhang, W, Siprachanh, C, Kanki, H, Atkinson, JB, King, P, Anderson, ME, Kupershmidt, S, Roden, DM. Atrial fibrillation in KCNE1-null mice. Circ Res, 97(1), 62-9, 2005.

Todd, SJ, Campbell, MJ, Roden, DM, Kannankeril, PJ. Novel Brugada SCN5A mutation causing sudden death in children. Heart Rhythm, 2(5), 540-3, 2005.

Drolet, Benoit, Simard, Chantale, Roden, Dan M. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation, 109(1), 26-9, 2004.

Fenichel, RR, Malik, M, Antzelevitch, C, Sanguinetti, M, Roden, DM, Priori, SG, Ruskin, JN, Lipicky, RJ, Cantilena, LR, , . Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol, 15(4), 475-95, 2004. PMCID:1544371

Jay, PY, Harris, BS, Maguire, CT, Buerger, A, Wakimoto, H, Tanaka, M, Kupershmidt, S, Roden, DM, Schultheiss, TM, O'Brien, TX, Gourdie, RG, Berul, CI, Izumo, S. Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. J Clin Invest, 113(8), 1130-7, 2004. PMCID:385399

Kanki, H, Kupershmidt, S, Yang, T, Wells, S, Roden, DM. A structural requirement for processing the cardiac K+ channel KCNQ1. J Biol Chem, 279(32), 33976-83, 2004.

Kannankeril, PRINCE J., Roden, DAN M., Fish, FRANK A.. Suppression of Bidirectional Ventricular Tachycardia and Unmasking of Prolonged QT interval with Verapamil in Andersen''s Syndrome. J Cardiovasc Electrophysiol, 15(1), 119, 2004.

Petersen, CI, McFarland, TR, Stepanovic, SZ, Yang, P, Reiner, DJ, Hayashi, K, George, AL, Roden, DM, Thomas, JH, Balser, JR. In vivo identification of genes that modify ether-a-go-go-related gene activity in Caenorhabditis elegans may also affect human cardiac arrhythmia. Proc Natl Acad Sci U S A, 101(32), 11773-8, 2004. PMCID:511051

Roden, DM. Human genomics and its impact on arrhythmias. Trends Cardiovasc Med, 14(3), 112-6, 2004.

Roden, Dan M. Drug-induced prolongation of the QT interval. N Engl J Med, 350(10), 1013-22, 2004.

Yang, Ping, Kupershmidt, Sabina, Roden, Dan M. Cloning and initial characterization of the human cardiac sodium channel (SCN5A) promoter. Cardiovasc Res, 61(1), 56-65, 2004.

Arad, Michael, Moskowitz, Ivan P, Patel, Vickas V, Ahmad, Ferhaan, Perez-Atayde, Antonio R, Sawyer, Douglas B, Walter, Mark, Li, Guo H, Burgon, Patrick G, Maguire, Colin T, Stapleton, David, Schmitt, Joachim P, Guo, X X, Pizard, Anne, Kupershmidt, Sabina, Roden, Dan M, Berul, Charles I, Seidman, Christine E, Seidman, J G. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation, 107(22), 2850-6, 2003.

Drolet, Benoit, Yang, Tao, Daleau, Pascal, Roden, Dan M, Turgeon, Jacques. Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol, 41(6), 934-7, 2003.

Johnson, Walter H, Yang, Ping, Yang, Tao, Lau, Yung R, Mostella, Barbara A, Wolff, Daynna J, Roden, Dan M, Benson, D Woodrow. Clinical, genetic, and biophysical characterization of a homozygous HERG mutation causing severe neonatal long QT syndrome. Pediatr Res, 53(5), 744-8, 2003.

Kondo, Richard P, Anderson, Robert H, Kupershmidt, Sabina, Roden, Dan M, Evans, Sylvia M. Development of the cardiac conduction system as delineated by minK-lacZ. J Cardiovasc Electrophysiol, 14(4), 383-91, 2003.

Kupershmidt, Sabina, Yang, Iris C-H, Hayashi, Kenshi, Wei, Jian, Chanthaphaychith, Siprachanh, Petersen, Christina I, Johns, Daivid C, George, Alfred L, Roden, Dan M, Balser, Jeffrey R. The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines. FASEB J, 17(15), 2263-5, 2003.

Laohakunakorn, P, Benson, DW, Yang, P, Yang, T, Roden, DM, Kugler, JD. Bidirectional ventricular tachycardia and channelopathy. Am J Cardiol, 92(8), 991-5, 2003.

Roden, Dan M. Antiarrhythmic drugs: past, present and future. J Cardiovasc Electrophysiol, 14(12), 1389-96, 2003.

Roden, Dan M. Cardiovascular pharmacogenomics. Circulation, 108(25), 3071-4, 2003.

Roden, Dan M. A surprising new arrhythmia mechanism in heart failure. Circ Res, 93(7), 589-91, 2003.

Roden, Dan M. Genetic polymorphisms, drugs, and proarrhythmia. J Interv Card Electrophysiol, 9(2), 131-5, 2003.

Roden, Dan M. Antiarrhythmic drugs: past, present, and future. Pacing Clin Electrophysiol, 26(12), 2340-9, 2003.

Yang, Tao, Kanki, Hideaki, Roden, Dan M. Phosphorylation of the IKs channel complex inhibits drug block: novel mechanism underlying variable antiarrhythmic drug actions. Circulation, 108(2), 132-4, 2003.

Anderson, Mark E, Al-Khatib, Sana M, Roden, Dan M, Califf, Robert M, , . Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J, 144(5), 769-81, 2002.

Gbadebo, T David, Trimble, Robert W, Khoo, Michelle S C, Temple, Joel, Roden, Dan M, Anderson, Mark E. Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. Circulation, 105(6), 770-4, 2002.

Kanki, Hideaki, Yang, Ping, Xie, Hong-Guang, Kim, Richard B, George, Alfred L, Roden, Dan M. Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. J Cardiovasc Electrophysiol, 13(3), 252-6, 2002.

Kupershmidt, Sabina, Yang, Iris C-H, Sutherland, Margaret, Wells, K Sam, Yang, Tao, Yang, Ping, Balser, Jeffrey R, Roden, Dan M. Cardiac-enriched LIM domain protein fhl2 is required to generate I(Ks) in a heterologous system. Cardiovasc Res, 56(1), 93-103, 2002.

Kupershmidt, Sabina, Yang, Tao, Chanthaphaychith, Siprachanh, Wang, Zhiqing, Towbin, Jeffrey A, Roden, Dan M. Defective human Ether-? -go-go-related gene trafficking linked to an endoplasmic reticulum retention signal in the C terminus. J Biol Chem, 277(30), 27442-8, 2002.

Roden, Dan M. The problem, challenge and opportunity of genetic heterogeneity in monogenic diseases predisposing to sudden death. J Am Coll Cardiol, 40(2), 357-9, 2002.

Roden, Dan M, Balser, Jeffrey R, George, Alfred L, Anderson, Mark E. Cardiac ion channels. Annu Rev Physiol, 64, 431-75, 2002.

Roden, Dan M, George, Alfred L. The genetic basis of variability in drug responses. Nat Rev Drug Discov, 1(1), 37-44, 2002.

Tan, Hanno L, Kupershmidt, Sabina, Zhang, Rong, Stepanovic, Svetlana, Roden, Dan M, Wilde, Arthur A M, Anderson, Mark E, Balser, Jeffrey R. A calcium sensor in the sodium channel modulates cardiac excitability. Nature, 415(6870), 442-7, 2002.

Wu, Yuejin, Temple, Joel, Zhang, Rong, Dzhura, Igor, Zhang, Wei, Trimble, Robert, Roden, Dan M, Passier, Robert, Olson, Eric N, Colbran, Roger J, Anderson, Mark E. Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation, 106(10), 1288-93, 2002.

Yang, Ping, Kanki, Hideaki, Drolet, Benoit, Yang, Tao, Wei, Jian, Viswanathan, Prakash C, Hohnloser, Stefan H, Shimizu, Wataru, Schwartz, Peter J, Stanton, Marshall, Murray, Katherine T, Norris, Kris, George, Alfred L, Roden, Dan M. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation, 105(16), 1943-8, 2002.

Anderson, M E, Mazur, A, Yang, T, Roden, D M. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther, 296(3), 806-10, 2001.

Darbar, D, Fromm, M F, Dellorto, S, Roden, D M. Sympathetic activation enhances QT prolongation by quinidine. J Cardiovasc Electrophysiol, 12(1), 9-14, 2001.

Mazur, A, Anderson, M E, Bonney, S, Roden, D M. Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J Am Coll Cardiol, 37(4), 1100-5, 2001.

Roden, D M. Defective ion channel function in the long QT syndrome: multiple unexpected mechanisms. J Mol Cell Cardiol, 33(2), 185-7, 2001.

Roden, D M. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res, 50(2), 224-31, 2001.

Roden, D M. Principles in pharmacogenetics. Epilepsia, 42 Suppl 5, 44-8, 2001.

Roden, D M, Brown, N J. Preprescription genotyping: not yet ready for prime time, but getting there. Circulation, 103(12), 1608-10, 2001.

Roden, DM. QT bumps: unraveling the mechanisms. J Cardiovasc Electrophysiol, 12(12), 1379-80, 2001.

Viswanathan, P C, Bezzina, C R, George, A L, Roden, D M, Wilde, A A, Balser, J R. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. Circulation, 104(10), 1200-5, 2001.

Wu, J, Roden, D M, Wikswo, J P. Delayed activation and retrograde propagation in cardiac muscle: implication of virtual electrode effects. Ann Biomed Eng, 28(11), 1318-25, 2001.

Yang, T, Snyders, D, Roden, D M. Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol, 38(5), 737-44, 2001.

Camm, A J, Janse, M J, Roden, D M, Rosen, M R, Cinca, J, Cobbe, S M. Congenital and acquired long QT syndrome. Eur Heart J, 21(15), 1232-7, 2000.

Chiang, C E, Roden, D M. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol, 36(1), 1-12, 2000.

Roden, D M. Impact of recent molecular studies on evaluation of ventricular arrhythmias. J Interv Card Electrophysiol, 4 Suppl 1, 7-16, 2000.

Roden, D M. Acquired long QT syndromes and the risk of proarrhythmia. J Cardiovasc Electrophysiol, 11(8), 938-40, 2000.

Roden, D M. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart, 84(3), 339-46, 2000. PMCID:1760959

Roden, D M, Anderson, M E. The pause that refreshes, or does it? Mechanisms in torsades de pointes. Heart, 84(3), 235-7, 2000. PMCID:1760962

Sesti, F, Abbott, G W, Wei, J, Murray, K T, Saksena, S, Schwartz, P J, Priori, S G, Roden, D M, George, A L, Goldstein, S A. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A, 97(19), 10613-8, 2000. PMCID:27073

Tan HL, Kupershmidt S, Zhang R, Stepanovic S, Roden DM, Wilde AAM, Anderson ME, Balser JR. A Calcium Sensor in the Sodium Channel Modulates Cardiac Excitability. Nature, 415, 442-447, 2000.

Wei, J, Fish, F A, Myerburg, R J, Roden, D M, George, A L. Novel KCNQ1 mutations associated with recessive and dominant congenital long QT syndromes: evidence for variable hearing phenotype associated with R518X. Hum Mutat, 15(4), 387-8, 2000.

Wilde, A A, Roden, D M. Predicting the long-QT genotype from clinical data: from sense to science. Circulation, 102(23), 2796-8, 2000.

Choy, A M, Darbar, D, Dell''Orto, S, Roden, D M. Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol, 34(2), 396-401, 1999.

Fromm, M F, Darbar, D, Dell''Orto, S, Roden, D M. Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading. J Pharmacol Exp Ther, 290(1), 253-8, 1999.

Fromm, M F, Kim, R B, Stein, C M, Wilkinson, G R, Roden, D M. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments. Circulation, 99(4), 552-7, 1999.

Fromm, M F, Leake, B, Roden, D M, Wilkinson, G R, Kim, R B. Human MRP3 transporter: identification of the 5''-flanking region, genomic organization and alternative splice variants. Biochim Biophys Acta, 1415(2), 369-74, 1999.

Kim, R B, Wandel, C, Leake, B, Cvetkovic, M, Fromm, M F, Dempsey, P J, Roden, M M, Belas, F, Chaudhary, A K, Roden, D M, Wood, A J, Wilkinson, G R. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res, 16(3), 408-14, 1999.

Kupershmidt S, Yang T, Anderson ME, Wessels A, Niswender KD, Magnuson MA, Roden DM. Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system. Circulation Research, 84, 146-152, 1999.

Kupershmidt, S, Yang, T, Anderson, M E, Wessels, A, Niswender, K D, Magnuson, M A, Roden, D M. Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system. Circ Res, 84(2), 146-52, 1999.

Mazur, A, Roden, D M, Anderson, M E. Systemic administration of calmodulin antagonist W-7 or protein kinase A inhibitor H-8 prevents torsade de pointes in rabbits. Circulation, 100(24), 2437-42, 1999.

Nattel, S, Roden, D M, Escande, D. A spotlight on electrophysiological remodeling and the molecular biology of ion channels. Cardiovasc Res, 42(2), 267-9, 1999.

Priori, S G, Barhanin, J, Hauer, R N, Haverkamp, W, Jongsma, H J, Kleber, A G, McKenna, W J, Roden, D M, Rudy, Y, Schwartz, K, Schwartz, P J, Towbin, J A, Wilde, A. Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. Eur Heart J, 20(3), 174-95, 1999.

Priori, S G, Barhanin, J, Hauer, R N, Haverkamp, W, Jongsma, H J, Kleber, A G, McKenna, W J, Roden, D M, Rudy, Y, Schwartz, K, Schwartz, P J, Towbin, J A, Wilde, A M. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation, 99(4), 518-28, 1999.

Priori, S G, Barhanin, J, Hauer, R N, Haverkamp, W, Jongsma, H J, Kleber, A G, McKenna, W J, Roden, D M, Rudy, Y, Schwartz, K, Schwartz, P J, Towbin, J A, Wilde, A M. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. Circulation, 99(5), 674-81, 1999.

Roden, D M. Mechanisms underlying variability in response to drug therapy: implications for amiodarone use. Am J Cardiol, 84(9A), 29R-36R, 1999.

Roden, D M. An overview of contemporary approaches to antiarrhythmic therapy. Jpn Circ J, 63(9), 655-8, 1999.

Roden, D M, Balser, J R. A plethora of mechanisms in the HERG-related long QT syndrome. Genetics meets electrophysiology. Cardiovasc Res, 44(2), 242-6, 1999.

Roden, D M, Kupershmidt, S. From genes to channels: normal mechanisms. Cardiovasc Res, 42(2), 318-26, 1999.

Roden, D M, Spooner, P M. Inherited long QT syndromes: a paradigm for understanding arrhythmogenesis. J Cardiovasc Electrophysiol, 10(12), 1664-83, 1999.

Roden, D M, Wilde, A A. Drug-induced J point elevation: a marker for genetic risk of sudden death or ECG curiosity. J Cardiovasc Electrophysiol, 10(2), 219-23, 1999.

Wei, J, Wang, D W, Alings, M, Fish, F, Wathen, M, Roden, D M, George, A L. Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Circulation, 99(24), 3165-71, 1999.

Wu, Y, Roden, D M, Anderson, M E. Calmodulin kinase inhibition prevents development of the arrhythmogenic transient inward current. Circ Res, 84(8), 906-12, 1999.

Choy, A M, Lang, C C, Roden, D M, Robertson, D, Wood, A J, Robertson, R M, Biaggioni, I. Abnormalities of the QT interval in primary disorders of autonomic failure. Am Heart J, 136(4 Pt 1), 664-71, 1998.

Darbar, D, Fromm, M F, Dell''Orto, S, Kim, R B, Kroemer, H K, Eichelbaum, M, Roden, D M. Modulation by dietary salt of verapamil disposition in humans. Circulation, 98(24), 2702-8, 1998.

Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest, 101, 289-294, 1998.

Kim, R B, Fromm, M F, Wandel, C, Leake, B, Wood, A J, Roden, D M, Wilkinson, G R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest, 101(2), 289-94, 1998. PMCID:508566

Kupershmidt S, Snyders DJ, Raes A, Roden DM. A K+ channel splice variant common in human heart lacks a C- terminal domain required for expression of rapidly-activating delayed rectifier current. J. Biol. Chem., 273, 27231-27235, 1998.

Kupershmidt S, Yang T, Roden DM. Modulation of cardiac sodium current phenotype by beta1-subunit expression. Circ , 83, 441-447, 1998.

Kupershmidt, S, Snyders, D J, Raes, A, Roden, D M. A K+ channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly activating delayed rectifier current. J Biol Chem, 273(42), 27231-5, 1998.

Kupershmidt, S, Yang, T, Roden, D M. Modulation of cardiac Na+ current phenotype by beta1-subunit expression. Circ Res, 83(4), 441-7, 1998.

Roden, D M. Cardiovascular and Renal Advisory Panel of the FDA. Circulation, 97(12), 1107, 1998.

Roden, D M. Taking the 'idio' out of 'idiosyncratic': predicting torsades de pointes. Pacing Clin Electrophysiol, 21(5), 1029-34, 1998.

Roden, D M. Mechanisms and management of proarrhythmia. Am J Cardiol, 82(4A), 49I-57I, 1998.

Thadani, U, Roden, D M. FDA Panel report: January 1998. Circulation, 97(23), 2295-6, 1998.

Vitola, J, Vukanovic, J, Roden, D M. Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol, 9(10), 1109-13, 1998.

Choy, A M, Lang, C C, Chomsky, D M, Rayos, G H, Wilson, J R, Roden, D M. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation, 96(7), 2149-54, 1997.

Darbar, D, Dell''Orto, S, M??rike, K, Wilkinson, G R, Roden, D M. Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther, 61(3), 292-300, 1997.

Kupershmidt ,S., Sutherland, M., King, D., Magnuson,M.A., Roden, D.M. Replacement by homologous recombination of the minK gene with lacZ reveals cell-specific minK expression. Biophys. J, 72, A226, 1997.

Roden, D M. A practical approach to torsade de pointes. Clin Cardiol, 20(3), 285-90, 1997.

Roden, D M, George, A L. Structure and function of cardiac sodium and potassium channels. Am J Physiol, 273(2 Pt 2), H511-25, 1997.

Yang, T, Snyders, D J, Roden, D M. Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ Res, 80(6), 782-9, 1997.

Yang, T, Snyders, D J, Roden, D M. Inhibition of cardiac potassium currents by the vesnarinone analog OPC-18790: comparison with quinidine and dofetilide. J Pharmacol Exp Ther, 280(3), 1170-5, 1997.

Yang, T., Snyders, D.J., Roden, D.M. Rapid inactivation determines the rectification and [K+]o-dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ. Res., 80, 782-789, 1997.

Yang, T., Snyders, D.J., Roden, D.M. Inhibition of cardiac potassium currents by the vesnarinone analog OPC- 18790: Comparison with quinidine and dofetilide. J. Phannacol.Exp. Ther., 280, 1170-1175, 1997.

Choy, A.M.J., Darbar, D., Dell'Orto, S., Roden, D.M. Increased sensitivity to QT prolonging drug therapy immediately after cardioversion to sinus rhythm. Circulation, 94, 1202, 1996.

Darbar, D, Dell''Orto, S, Wilkinson, G R, Roden, D M. Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. Am J Health Syst Pharm, 53(6), 655-8, 1996.

Darbar, D, Smith, M, M??rike, K, Roden, D M. Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. Am J Cardiol, 77(15), 1351-5, 1996.

Darbar, D., Smith, M., M?rike, K., Roden, D.M. Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pre-treatment with propranolol and diltiazem. Am. J. Cardiol, 77, 1351-1355, 1996.

Fritz, JD, Robertson, D. Gene targeting approaches to the autonomic nervous system. J Auton Nerv Syst, 61(1), 1-5, 1996.

Kennedy, C J, Roden, D M, McAllister, I L. Suprachoroidal effusion following argon laser trabeculoplasty. Aust N Z J Ophthalmol, 24(3), 279-82, 1996.

Roden, D M. Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates. Am J Cardiol, 78(4A), 12-6, 1996.

Roden, D M. Is there a need for new antiarrhythmic drugs. Arch Mal Coeur Vaiss, 89 Spec No 1, 13-8, 1996.

Roden, D M. Ibutilide and the treatment of atrial arrhythmias. A new drug--almost unheralded--is now available to US physicians. Circulation, 94(7), 1499-502, 1996.

Roden, D M, George, A L. The cardiac ion channels: relevance to management of arrhythmias. Annu Rev Med, 47, 135-48, 1996.

Roden, D M, Lazzara, R, Rosen, M, Schwartz, P J, Towbin, J, Vincent, G M. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation, 94(8), 1996-2012, 1996.

Roden, D.M. Ibutilide and treatment of atrial arrhythmias (Editorial). Circulation, 94, 1499-1502, 1996.

Roden, D.M., George, A.L. Jr. The cardiac ion channels: Relevance to management of arrhythmias. Annu. Rev. Med, 47, 135-148, 1996.

Roden, D.M., Lazzara, R., Rosen, M.R., Schwartz, P.J., Vincent, G.M., for the SADS Foundation Task Force on LQTS. Multiple mechanisms in the long QT syndrome: Current knowledge, gaps, and future directions. Circulation, 94, 1996-2012, 1996.

Rogers, RD, Bond, AH, Roden, DM. Structural Chemistry of Poly(ethylene glycol) Complexes of Lead(II) Nitrate and Lead(II) Bromide. Inorg Chem, 35(24), 6964-6973, 1996.

Yang, T, Roden, D M. Regulation of sodium current development in cultured atrial tumor myocytes (AT-1 cells). Am J Physiol, 271(2 Pt 2), H541-7, 1996.

Yang, T, Roden, D M. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation, 93(3), 407-11, 1996.

Yang, T., Roden, D.M. Extracellular potassium modulation of drug block of IKr: Implications for Torsades de Pointes and reverse use-dependence. Circulation, 93, 407-411, 1996.

Yang, T., Roden, D.M. Regulation of sodium current development in cultured atrial tumor myocytes (AT-1 cells). Am. J. Physiol, 271, H541-H547, 1996.

Echt, D S, Lee, J T, Murray, K T, Vorperian, V, Borganelli, S M, Crawford, D M, Friedrich, T, Roden, D M. A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J Cardiovasc Electrophysiol, 6(9), 687-99, 1995.

Echt, D.S., Lee, J.T., Murray, K.T., Vorperian, V., Borganelli, S.M., Crawford, D.M., Friedrich, T., Roden, D.M. A randomized, double-blind, placebo-controlled dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J. Cardiovasc. Electrophys, 6, 687-699, 1995.

Roden, D M, George, A L, Bennett, P B. Recent advances in understanding the molecular mechanisms of the long QT syndrome. J Cardiovasc Electrophysiol, 6(11), 1023-31, 1995.

Roden, D.M. Antiarrhythmic drugs. The Pharmacological Basis of Therapeutics, 9th Edition, 839-874, 1995.

Roden, D.M., George, A.L. Jr, Bennett, P.B. Recent advances in understanding the molecular mechanisms of the long QT syndrome. Invited review. J. Cardiovasc. Electrophysiol, 6, 1023-1031, 1995.

Wei, J., Wathen, M., Murray, K., Daw, R., Roden, D., George, A.L. Jr. Absence of HERG and SCN5A mutations in acquired long QT syndrome. Circulation, 92, 1-275, 1995.

Yang, T, Kupershmidt, S, Roden, D M. Anti-minK antisense decreases the amplitude of the rapidly activating cardiac delayed rectifier K+ current. Circ Res, 77(6), 1246-53, 1995.

Yang, T, Prakash, C, Roden, D M, Snyders, D J. Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. Br J Pharmacol, 115(2), 267-74, 1995. PMCID:1908306

Yang, T, Snyders, D J, Roden, D M. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation, 91(6), 1799-806, 1995.

Yang, T., Kupershmidt, S., Roden, D.M. Anti-minK antisense decreases the amplitude of the rapidly-activating cardiac delayed rectifier K+ current. Circ. Res, 77, 1246-1253, 1995.

Yang, T., Prakash, C., Roden, D.M., Snyders, D.J. Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. J. Pharmacol, 15, 267-274, 1995.

Yang, T., Snyders, D.J., Roden, D.M. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly-activating delayed rectifier K+ current (IKr) in AT- I cells: Concentration-, time-, voltage- and use-dependent effects. Circulation, 91, 1799-1806, 1995.

Echt, D S, Gremillion, S T, Lee, J T, Roden, D M, Murray, K T, Borganelli, M, Crawford, D M, Stewart, J R, Hammon, J W. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices. J Cardiovasc Electrophysiol, 5(9), 752-60, 1994.

M??rike, K E, Roden, D M. Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects. Clin Pharmacol Ther, 55(1), 28-34, 1994.

Roden, D M. Mirror, mirror on the wall ... stereochemistry in therapeutics. Circulation, 89(5), 2451-3, 1994.

Roden, D M. Risks and benefits of antiarrhythmic therapy. N Engl J Med, 331(12), 785-91, 1994.

Roden, D M, Levy, F E. Oncocytoma of the parotid gland presenting with nerve paralysis. Otolaryngol Head Neck Surg, 110(6), 587-90, 1994.

Roden, D.M. Risks and benefits of antiarrhythmic therapy. Invited review. N. Engl. J. Med., , 331, 785-791, 1994.

Roden, D.M. Mirror, mirror on the wall: Stereochemistry in therapeutics (Editorial). Circulation, 89, 2451-2453, 1994.

Roden, D.M., Murray, K.T. Pharmacokinetics, phannacodynamics and pharmacogenetics. Zipes, D.P., Jalife, J. (eds): Cardiac Electrophysiology: From Cell to Bedside, 2nd edition, W.B. Saunders, , 1287-1296, 1994.

Roden, D.M., Tamkun, M.M. Toward a molecular view of cardiac arrhythmogenesis. Trends Cardiovasc. Med. , 4, 278-285, 1994.

Turgeon, J, Daleau, P, Bennett, P B, Wiggins, S S, Selby, L, Roden, D M. Block of IKs, the slow component of the delayed rectifier K+ current, by the diuretic agent indapamide in guinea pig myocytes. Circ Res, 75(5), 879-86, 1994.

Turgeon, J., Daleau, P., Bennett, P.B., Wiggins, S.S., Selby, L., Roden, D.M. Block of IKs, the slow component of the delayed rectifier K+ current, by the diuretic agent indapamide in guinea pig myocytes. Circ. Res, 75, 879-886, 1994.

Vorperian, V R, Wisialowski, T A, Deegan, R, Roden, D M. Effect of hypercapnic acidemia on anisotropic propagation in the canine ventricle. Circulation, 90(1), 456-61, 1994.

Yang, T, Wathen, M S, Felipe, A, Tamkun, M M, Snyders, D J, Roden, D M. K+ currents and K+ channel mRNA in cultured atrial cardiac myocytes (AT-1 cells). Circ Res, 75(5), 870-8, 1994.

Yang, T., Wathen, M.S., Felipe, A., Tamkun, M.M., Snyders, D.J., Roden, D.M. K+ currents and K+ channel mRNA in cultured atrial cardiac myocytes (AT-1 cells). Circ. Res, 75, 870-878, 1994.

Davies, R F, Siddoway, L A, Shaw, L, Barbey, J T, Roden, D M, Woosley, R L. Immediate- versus controlled-release disopyramide: importance of saturable binding. Clin Pharmacol Ther, 54(1), 16-22, 1993.

Roden, D M. Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization. Eur Heart J, 14 Suppl H, 56-61, 1993.

Roden, D M. Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol, 72(16), 45F-50F, 1993.

Roden, D M. Torsade de pointes. Clin Cardiol, 16(9), 683-6, 1993.

Roden, D M. Current status of class III antiarrhythmic drug therapy. Am J Cardiol, 72(6), 44B-49B, 1993.

Roden, D M. Usefulness of sotalol for life-threatening ventricular arrhythmias. Am J Cardiol, 72(4), 51A-55A, 1993.

Roden, D M, Pomerantz, R A. Penetrating injuries to the neck: a safe, selective approach to management. Am Surg, 59(11), 750-3, 1993.

Birgersdotter, U M, Wong, W, Turgeon, J, Roden, D M. Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. Br J Clin Pharmacol, 33(3), 275-80, 1992. PMCID:1381275

Greene, H L, Roden, D M, Katz, R J, Woosley, R L, Salerno, D M, Henthorn, R W. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. J Am Coll Cardiol, 19(5), 894-8, 1992.

Turgeon, J, Wisialowski, T A, Wong, W, Altemeier, W A, Wikswo, J P, Roden, D M. Suppression of longitudinal versus transverse conduction by sodium channel block. Effects of sodium bolus. Circulation, 85(6), 2221-6, 1992.

Wong, W, Pavlou, H N, Birgersdotter, U M, Hilleman, D E, Mohiuddin, S M, Roden, D M. Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. Am J Cardiol, 69(3), 206-12, 1992.

Balser, J R, Bennett, P B, Hondeghem, L M, Roden, D M. Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. Circ Res, 69(2), 519-29, 1991.

Balser, J R, Roden, D M, Bennett, P B. Single inward rectifier potassium channels in guinea pig ventricular myocytes. Effects of quinidine. Biophys J, 59(1), 150-61, 1991. PMCID:1281127

Balser, J.R., Bennett, P.B., Hondeghem, L.M., Roden, D.M. Suppression of time-dependent outward current in guinea pig ventricular myocytes: Actions of quinidine and amiodarone. Circ. Res., 69, 519-529, 1991.

Pavlou, H N, Funck-Brentano, C, Lineberry, M D, Woosley, R L, Roden, D M. Prospective pharmacokinetically based development of effective infusion regimens for ACC-9358, a new antiarrhythmic drug. Clin Pharmacol Ther, 49(3), 314-21, 1991.

Tamkun, M M, Knoth, K M, Walbridge, J A, Kroemer, H, Roden, D M, Glover, D M. Molecular cloning and characterization of two voltage-gated K+ channel cDNAs from human ventricle. FASEB J, 5(3), 331-7, 1991.

Turgeon, J, Evans, W E, Relling, M V, Wilkinson, G R, Roden, D M. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. Br J Clin Pharmacol, 32(3), 283-8, 1991. PMCID:1368519

Turgeon, J, Funck-Brentano, C, Gray, H T, Pavlou, H N, Prakash, C, Blair, I A, Roden, D M. Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers. Clin Pharmacol Ther, 49(5), 488-96, 1991.

Ware, D L, Lee, J T, Murray, K T, Hanyok, J J, Roden, D M, Echt, D S. Intravenous 3-methoxy-O-desmethyl-encainide in reentrant supraventricular tachycardia: a randomized double-blind placebo-controlled trial in patients undergoing EP study. Pacing Clin Electrophysiol, 14(9), 1343-50, 1991.

Wikswo, J P, Wisialowski, T A, Altemeier, W A, Balser, J R, Kopelman, H A, Roden, D M. Virtual cathode effects during stimulation of cardiac muscle. Two-dimensional in vivo experiments. Circ Res, 68(2), 513-30, 1991.

Balser, J R, Bennett, P B, Roden, D M. Time-dependent outward current in guinea pig ventricular myocytes. Gating kinetics of the delayed rectifier. J Gen Physiol, 96(4), 835-63, 1990. PMCID:2229010

Balser, J R, Roden, D M, Bennett, P B. Global parameter optimization for cardiac potassium channel gating models. Biophys J, 57(3), 433-44, 1990. PMCID:1280738

Balser, J.R., Bennett, P.B., Roden, D.M. Time-dependent outward current in guinea pig myocytes: Gating kinetics of the delayed rectifier. J. Gen. Physiol, 96, 835-863, 1990.

Campbell, R M, Woosley, R L, Iansmith, D H, Roden, D M. Lack of triggered automaticity despite repolarization abnormalities due to bepridil and lidoflazine. Pacing Clin Electrophysiol, 13(1), 30-6, 1990.

Fish, F A, Prakash, C, Roden, D M. Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose potassium channel activators. Circulation, 82(4), 1362-9, 1990.

Funck-Brentano, C, Kroemer, H K, Lee, J T, Roden, D M. Propafenone. N Engl J Med, 322(8), 518-25, 1990.

Funck-Brentano, C, Silberstein, D J, Roden, D M, Wood, A J, Woosley, R L. A mechanism of D-(+)-sotalol effects on heart rate not related to beta-adrenoceptor antagonism. Br J Clin Pharmacol, 30(2), 195-202, 1990. PMCID:1368218

Lee, J T, Kroemer, H K, Silberstein, D J, Funck-Brentano, C, Lineberry, M D, Wood, A J, Roden, D M, Woosley, R L. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med, 322(25), 1764-8, 1990.

Murray, K T, Reilly, C, Koshakji, R P, Roden, D M, Lineberry, M D, Wood, A J, Siddoway, L A, Barbey, J T, Woosley, R L. Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. J Clin Invest, 85(3), 836-42, 1990. PMCID:296501

Turgeon, J, Kroemer, H K, Prakash, C, Blair, I A, Roden, D M. Stereoselective determination of flecainide in human plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Sci, 79(2), 91-5, 1990.

Turgeon, J, Pavlou, H N, Wong, W, Funck-Brentano, C, Roden, D M. Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. J Pharmacol Exp Ther, 255(2), 642-9, 1990.

Zhou, H H, Anthony, L B, Roden, D M, Wood, A J. Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin Pharmacol Ther, 47(6), 686-93, 1990.

Bajaj, A K, Woosley, R L, Roden, D M. Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide. Circulation, 80(4), 994-1002, 1989.

Davies, R F, Lineberry, M D, Funck-Brentano, C, Echt, D S, Lee, J T, Capuzzi, D M, Roden, D M, Woosley, R L. Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias. Clin Pharmacol Ther, 46(3), 324-34, 1989.

Fish, F A, Roden, D M. A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs. Med Toxicol Adverse Drug Exp, 4(6), 400-11, 1989.

Funck-Brentano, C, Kroemer, H K, Pavlou, H, Woosley, R L, Roden, D M. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol, 27(4), 435-44, 1989. PMCID:1379722

Funck-Brentano, C, Light, R T, Lineberry, M D, Wright, G M, Roden, D M, Woosley, R L. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans. J Cardiovasc Pharmacol, 14(3), 364-73, 1989.

Funck-Brentano, C, Turgeon, J, Woosley, R L, Roden, D M. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther, 249(1), 134-42, 1989.

Greene, H L, Richardson, D W, Barker, A H, Roden, D M, Capone, R J, Echt, D S, Friedman, L M, Gillespie, M J, Hallstrom, A P, Verter, J. Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (the Cardiac Arrhythmia Pilot Study). Am J Cardiol, 63(1), 1-6, 1989.

Greene, H L, Richardson, D W, Hallstrom, A P, McBride, R, Capone, R J, Barker, A H, Roden, D M, Echt, D S. Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study). Am J Cardiol, 63(7), 393-8, 1989.

Kroemer, H K, Funck-Brentano, C, Silberstein, D J, Wood, A J, Eichelbaum, M, Woosley, R L, Roden, D M. Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation, 79(5), 1068-76, 1989.

Kroemer, H K, Turgeon, J, Parker, R A, Roden, D M. Flecainide enantiomers: disposition in human subjects and electrophysiologic actions in vitro. Clin Pharmacol Ther, 46(5), 584-90, 1989.

Murray, K T, Barbey, J T, Kopelman, H A, Siddoway, L A, Echt, D S, Woosley, R L, Roden, D M. Mexiletine and tocainide: a comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing. Clin Pharmacol Ther, 45(5), 553-61, 1989.

Roden, D M. Magnesium treatment of ventricular arrhythmias. Am J Cardiol, 63(14), 43G-46G, 1989.

Roden, D M, Lee, J T, Woosley, R L, Echt, D S. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation. Circulation, 80(5), 1247-58, 1989.

The CAST Investigators. Preliminary Report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. 321, N. Eng. J. Med, 406-412, 1989.

Turgeon, J, Funck-Brentano, C, Gray, H T, Roden, D M. Improved high-performance liquid chromatographic assay for encainide and its metabolites in human body fluids. J Chromatogr, 490(1), 165-74, 1989.

Turgeon, J, Roden, D M. Pharmacokinetic profile of encainide. Clin Pharmacol Ther, 45(6), 692-4, 1989.

Barbey, J T, Thompson, K A, Echt, D S, Woosley, R L, Roden, D M. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. Circulation, 77(2), 380-91, 1988.

Barbey, J T, Thompson, K A, Echt, D S, Woosley, R L, Roden, D M. Tocainide plus quinidine for treatment of ventricular arrhythmias. Am J Cardiol, 61(8), 570-3, 1988.

Kopelman, H A, Woosley, R L, Lee, J T, Roden, D M, Echt, D S. Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease. Am J Cardiol, 61(13), 1006-11, 1988.

Roden, D M. Role of the electrocardiogram in determining electrophysiologic end points of drug therapy. Am J Cardiol, 62(12), 34H-38H, 1988.

Roden, D M, Bennett, P B, Snyders, D J, Balser, J R, Hondeghem, L M. Quinidine delays IK activation in guinea pig ventricular myocytes. Circ Res, 62(5), 1055-8, 1988.

Roden, D M, Nadeau, J H, Primm, R K. Electrophysiologic and hemodynamic effects of chronic oral therapy with the alpha 2-agonists clonidine and tiamenidine in hypertensive volunteers. Clin Pharmacol Ther, 43(6), 648-54, 1988.

Roden, D M, Woosley, R L. Clinical pharmacokinetics of encainide. Clin Pharmacokinet, 14(3), 141-7, 1988.

Thompson, K A, Iansmith, D H, Siddoway, L A, Woosley, R L, Roden, D M. Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers. J Pharmacol Exp Ther, 244(3), 950-5, 1988.

Thompson, K A, Murray, J J, Blair, I A, Woosley, R L, Roden, D M. Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. Clin Pharmacol Ther, 43(6), 636-42, 1988.

Wang, T, Siddoway, L A, Thompson, K A, Conard, G J, Bergstrand, R H, Kvam, D, Roden, D M, Woosley, R L. The development and testing of intravenous dosing regimens: application to flecainide for the suppression of ventricular arrhythmias. Clin Pharmacol Ther, 43(5), 499-508, 1988.

Woosley, R L, Wood, A J, Roden, D M. Drug therapy. Encainide. N Engl J Med, 318(17), 1107-15, 1988.

Bajaj, A K, Kopelman, H A, Wikswo, J P, Cassidy, F, Woosley, R L, Roden, D M. Frequency- and orientation-dependent effects of mexiletine and quinidine on conduction in the intact dog heart. Circulation, 75(5), 1065-73, 1987.

Roden, D M, Iansmith, D H. Effects of low potassium or magnesium concentrations on isolated cardiac tissue. Am J Med, 82(3A), 18-23, 1987.

Roden, D M, Iansmith, D H, Woosley, R L. Frequency-dependent interactions of mexiletine and quinidine on depolarization and repolarization in canine Purkinje fibers. J Pharmacol Exp Ther, 243(3), 1218-24, 1987.

Siddoway, L A, Barbey, J T, Roden, D M, Woosley, R L. Pharmacologic evaluation of standard and controlled-release disopyramide. Angiology, 38(2 Pt 2), 184-7, 1987.

Siddoway, L A, Thompson, K A, McAllister, C B, Wang, T, Wilkinson, G R, Roden, D M, Woosley, R L. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation, 75(4), 785-91, 1987.

Thompson, K A, Blair, I A, Woosley, R L, Roden, D M. Comparative in vitro electrophysiology of quinidine, its major metabolites and dihydroquinidine. J Pharmacol Exp Ther, 241(1), 84-90, 1987.

Woosley, R L, Roden, D M. Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs. Am J Cardiol, 59(11), 19E-25E, 1987.

Bergstrand, R H, Wang, T, Roden, D M, Avant, G R, Sutton, W W, Siddoway, L A, Wolfenden, H, Woosley, R L, Wilkinson, G R, Wood, A J. Encainide disposition in patients with chronic cirrhosis. Clin Pharmacol Ther, 40(2), 148-54, 1986.

Bergstrand, R H, Wang, T, Roden, D M, Stone, W J, Wolfenden, H T, Woosley, R L, Wilkinson, G R, Wood, A J. Encainide disposition in patients with renal failure. Clin Pharmacol Ther, 40(1), 64-70, 1986.

Duff, H J, Kolodgie, F D, Roden, D M, Woosley, R L. Electropharmacologic synergism with mexiletine and quinidine. J Cardiovasc Pharmacol, 8(4), 840-6, 1986.

Hammon, J W, Echt, D S, Merrill, W H, Primm, K R, Woosley, R L, Smith, R F, Roden, D M, Bender, H W. Indications for different modes of surgical therapy in medically refractory ventricular arrhythmias. Ann Surg, 203(6), 679-84, 1986. PMCID:1251204

Kolodgie, F D, Dawson, A K, Roden, D M, Forman, M B, Virmani, R. Effect of Fluosol-DA on infarct morphology and vulnerability to ventricular arrhythmia. Am Heart J, 112(6), 1192-201, 1986.

Roden, D M. Pharmacologic information required for design of programmed electrical stimulation protocols. Circulation, 73(2 Pt 2), II39-44, 1986.

Roden, D M, Thompson, K A, Hoffman, B F, Woosley, R L. Clinical features and basic mechanisms of quinidine-induced arrhythmias. J Am Coll Cardiol, 8(1 Suppl A), 73A-78A, 1986.

Roden, D M, Wood, A J, Wilkinson, G R, Woosley, R L. Disposition kinetics of encainide and metabolites. Am J Cardiol, 58(5), 4C-9C, 1986.

Roden, D M, Woosley, R L. Drug therapy. Tocainide. N Engl J Med, 315(1), 41-5, 1986.

Roden, D M, Woosley, R L. Drug therapy. Flecainide. N Engl J Med, 315(1), 36-41, 1986.

Roden, D M, Woosley, R L, Primm, R K. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J, 111(6), 1088-93, 1986.

Wang, T, Bergstrand, R H, Thompson, K A, Siddoway, L A, Duff, H J, Woosley, R L, Roden, D M. Concentration-dependent pharmacologic properties of sotalol. Am J Cardiol, 57(13), 1160-5, 1986.

Woosley, R L, Echt, D S, Roden, D M. Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. Am J Cardiol, 57(3), 25B-33B, 1986.

Woosley, R L, Roden, D M, Dai, G H, Wang, T, Altenbern, D, Oates, J, Wilkinson, G R. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clin Pharmacol Ther, 39(3), 282-7, 1986.

Duff, H J, Roden, D M, Carey, E L, Wang, T, Primm, R K, Woosley, R L. Spectrum of antiarrhythmic response to encainide. Am J Cardiol, 56(13), 887-91, 1985.

Duff, H J, Roden, D M, Yacobi, A, Robertson, D, Wang, T, Maffucci, R J, Oates, J A, Woosley, R L. Bretylium: relations between plasma concentrations and pharmacologic actions in high-frequency ventricular arrhythmias. Am J Cardiol, 55(4), 395-401, 1985.

Roden, D M. Antiarrhythmic drugs. Clinical pharmacology of the old and the new agents. Postgrad Med, 78(4), 28-37, 1985.

Roden, D M. Tocainide and mexiletine. Orally effective lidocaine analogues. Arch Intern Med, 145(3), 417-8, 1985.

Roden, D M, Hoffman, B F. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res, 56(6), 857-67, 1985.

Roden, D M, Woosley, R L. QT prolongation and arrhythmia suppression. Am Heart J, 109(2), 411-5, 1985.

Roden, D.M., Hoffman, B. Action potential prolongation and induction of abnormnal automaticity by low quinidine concentrations in canine Purkinje fibers: Relationship to potassium and cycle length. Circ. Res, 56, 857-867, 1985.

Siddoway, L A, Roden, D M, Woosley, R L. Clinical pharmacology of old and new antiarrhythmic drugs. Cardiovasc Clin, 15(3), 199-248, 1985.

Woosley, R L, Echt, D S, Roden, D M. Treatment of ventricular arrhythmias in the failing heart: pharmacologic and clinical considerations. Ration Drug Ther, 19(10), 1-7, 1985.

Carey, E L, Duff, H J, Roden, D M, Primm, R K, Wilkinson, G R, Wang, T, Oates, J A, Woosley, R L. Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. J Clin Invest, 73(2), 539-47, 1984. PMCID:425046

Dawson, A K, Roden, D M, Duff, H J, Woosley, R L, Smith, R F. Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog. Am J Cardiol, 54(6), 654-8, 1984.

Duff, H J, Oates, J A, Roden, D M, Woosley, R L. The antiarrhythmic activity of meobentine sulfate in man. J Cardiovasc Pharmacol, 6(4), 650-6, 1984.

Duff, H J, Roden, D M, Marney, S, Colley, D G, Maffucci, R, Primm, R K, Oates, J A, Woosley, R L. Molecular basis for the antigenicity of lidocaine analogs: tocainide and mexiletine. Am Heart J, 107(3), 585-9, 1984.

Riddell, J G, McAllister, C B, Wilkinson, G R, Wood, A J, Roden, D M. A new method for constant plasma drug concentrations: application to lidocaine. Ann Intern Med, 100(1), 25-8, 1984.

Roden, D M, Dawson, A K, Duff, H J, Woosley, R L, Smith, R F. Electrophysiology of O-demethyl encainide in a canine model of sustained ventricular tachycardia. J Cardiovasc Pharmacol, 6(4), 588-95, 1984.

Siddoway, L A, Roden, D M, Woosley, R L. Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. Am J Cardiol, 54(9), 9D-12D, 1984.

Wang, T, Roden, D M, Wolfenden, H T, Woosley, R L, Wood, A J, Wilkinson, G R. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther, 228(3), 605-11, 1984.

Woosley, R L, Cerskus, I, Roden, D M. Antiarrhythmic therapy: clinical pharmacology update. J Clin Pharmacol, 24(7), 295-305, 1984.

Woosley, R L, Siddoway, L A, Duff, H J, Roden, D M. Flecainide dose-response relations in stable ventricular arrhythmias. Am J Cardiol, 53(5), 59B-65B, 1984.

Woosley, R L, Siddoway, L A, Thompson, K, Cerskus, I, Roden, D M. Potential applications of free drug level monitoring in cardiovascular therapy. Clin Pharmacokinet, 9 Suppl 1, 79-83, 1984.

Duff, H J, Dawson, A K, Roden, D M, Oates, J A, Smith, R F, Woosley, R L. Electrophysiologic actions of O-demethyl encainide: an active metabolite. Circulation, 68(2), 385-91, 1983.

Duff, H J, Roden, D M, Brorson, L, Wood, A J, Dawson, A K, Primm, R K, Oates, J A, Smith, R F, Woosley, R L. Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. J Am Coll Cardiol, 2(6), 1134-40, 1983.

Roden, D M, Woosley, R L. Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide. Pharmacol Ther, 23(2), 179-91, 1983.

Siddoway, L A, McAllister, C B, Wilkinson, G R, Roden, D M, Woosley, R L. Amiodarone dosing: a proposal based on its pharmacokinetics. Am Heart J, 106(4 Pt 2), 951-6, 1983.

Woosley, R L, Roden, D M. Importance of metabolites in antiarrhythmic therapy. Am J Cardiol, 52(6), 3C-7C, 1983.

Duff, H J, Roden, D M, Dawson, A K, Oates, J A, Smith, R F, Woosley, R L. Comparison of the effects of placebo and encainide on programmed electrical stimulation and ventricular arrhythmia frequency. Am J Cardiol, 50(2), 305-12, 1982.

Roden, D M, Duff, H J, Altenbern, D, Woosley, R L. Antiarrhythmic activity of the O-demethyl metabolite of encainide. J Pharmacol Exp Ther, 221(3), 552-7, 1982.

Woosley, R L, Reele, S B, Roden, D M, Nies, A S, Oates, J A. Pharmacologic reversal of hypotensive effect complicating antiarrhythmic therapy with bretylium. Clin Pharmacol Ther, 32(3), 313-21, 1982.

Woosley, R L, Roden, D M, Duff, H J, Oates, J A. Selection of an antiarrhythmic drug for a sudden-death-prevention trial. Am Heart J, 103(4 Pt 2), 737-45, 1982.

Duff, H J, Roden, D M, Maffucci, R J, Vesper, B S, Conard, G J, Higgins, S B, Oates, J A, Smith, R F, Woosley, R L. Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am J Cardiol, 48(6), 1133-40, 1981.

Roden, D M, Duff, H J, Primm, R K, Kronenberg, M W, Woosley, R L. Control of ventricular preexcitation and associated arrhythmias by encainide. Am Heart J, 102(4), 794-7, 1981.

Roden, D M, Duff, H J, Reele, S B, Woosley, R L, Oates, J A, Smith, R F, Friesinger, G C. Recurrent ventricular tachycardia in the absence of overt heart disease: clinical characteristics and response to drug therapy. South Med J, 74(9), 1090-4, 1981.

Roden, D M, Reele, S B, Higgins, S B, Mayol, R F, Gammans, R E, Oates, J A, Woosley, R L. Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics. N Engl J Med, 302(16), 877-82, 1980.

Roden, D M, Reele, S B, Higgins, S B, Wilkinson, G R, Smith, R F, Oates, J A, Woosley, R L. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol, 46(3), 463-8, 1980.

Roden, D M, Roden, D M, Reele, S B, Reele, S B, Higgins, S B, Higgins, S B, Carr, R K, Carr, R K, Smith, R F, Smith, R F, Oates, J A, Oates, J A, Woosley, R L, Woosley, R L. Tocainide therapy for refractory ventricular arrhythmias. Am Heart J, 100(1), 15-22, 1980.


Postdoctoral Position Available
No

Postdoctoral Position Details
N/A

Updated Date
08/08/2012



Vanderbilt University is committed to principles of equal opportunity and affirmative action.
Copyright 2008 Vanderbilt University School of Medicine
The office of Biomedical Research Education & Training All rights reserved.
For questions or problems concerning this page, please submit a help ticket.